Welcome to our dedicated page for Solana Company SEC filings (Ticker: HSDT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Solana Company filings document a Delaware issuer with Nasdaq-listed Class A common stock and a business profile that includes a Solana (SOL) digital asset treasury following its history as Helius Medical Technologies. Recent 8-K reports cover operating results, staking-reward revenue, digital-asset fair value effects, capital actions, registered-direct equity financing, put-option arrangements, and outstanding common stock and pre-funded warrants.
Governance filings include director and officer changes, separation and employment arrangements, board composition, and definitive proxy materials for annual-meeting matters, executive compensation, equity awards, and shareholder voting items. The filings also describe the company’s expansion from its medical-device neurotechnology legacy into SOL holdings, staking, custody, and related infrastructure initiatives.
Helius Medical Technologies (Nasdaq: HSDT) filed an 8-K disclosing a 1-for-50 reverse stock split approved by shareholders and the board to regain compliance with Nasdaq’s minimum-bid requirement.
The split becomes effective at 5:00 p.m. ET on June 30 2025; trading will begin on a split-adjusted basis on July 1 2025. Outstanding shares will fall from roughly 33.8 million to 0.7 million, while authorized shares remain 150 million and par value stays $0.001.
- Fractional shares: rounded down for cash or rounded up to a whole share.
- Equity awards and warrants will be proportionally adjusted.
- New CUSIP: 42328V 876; transfer agent: Equiniti Trust.
The action, reported under Items 3.03 and 5.03, materially modifies holder rights and aims to avert a potential Nasdaq delisting.
Helius Medical Technologies, Inc. (Nasdaq: HSDT) filed a Form 8-K on June 23, 2025 to update investors on its Nasdaq listing status.
• Background: On March 31, 2025 Nasdaq Staff notified Helius that its stockholders’ equity had fallen below the required US$2.5 million, triggering a potential delisting under Listing Rule 5550(b)(1). After a subsequent hearing, Nasdaq granted the Company an extension until June 30, 2025 to regain compliance.
• Capital raise: Helius completed a public offering on June 6, 2025, generating net proceeds of approximately US$8.1 million.
• Current status: The Company has furnished an unaudited interim consolidated balance sheet dated June 17, 2025 that gives effect to the offering. Management states that the pro-forma balance sheet shows stockholders’ equity of at least US$2.5 million, which it believes restores compliance with the Nasdaq Stockholders’ Equity Requirement.
• Next steps: Helius is awaiting formal confirmation from Nasdaq that all continued-listing criteria— including the equity threshold—have been satisfied.
No earnings figures, segment data, or other financial statements were provided beyond the balance-sheet reference.
Helius Medical Technologies (NASDAQ: HSDT) has reported a significant amendment to its 2022 Equity Incentive Plan following stockholder approval at a special meeting held on May 23, 2025. The amendment, initially adopted by the Board on April 22, 2025, has resulted in a substantial increase in the company's equity compensation pool.
Key developments:
- The Plan's share pool increased to 7.1 million shares on June 16, 2025
- The increase represents 20% of Fully Diluted Shares following the company's first registered offering after May 15, 2025
- The amendment was triggered by the completion of a Public Offering
This expansion of the equity incentive plan suggests Helius Medical Technologies is strengthening its ability to attract and retain talent through equity-based compensation. The significant increase in available shares indicates the company's commitment to aligning employee interests with shareholder value.